Z6·尊龙凯时「中国」官方网站Z6·尊龙凯时

CN
News & Reports

News and Reports

Select year

2024 2023 2022 2021 2020 Earlier
shown/page
5
5 10 15 20

2024.10.17

Chipscreen Biosesciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosesciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

Full text

2024.10.15

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

Full text

2024.04.30

National Medical Products Administration (NMPA) Approves Chipscreen Biosescience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
National Medical Products Administration (NMPA) Approves Chipscreen Biosescience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

Full text

2024.03.18

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

Full text

2024.03.04

CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer
CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer

Full text
Media contact

Media contact

  • Media contact

    （+86）0755-36993500

  • Media contact

    pr@cnzywx.com

Z6·尊龙凯时